Visit our website

Resqcol Duo

Improve your intestinal health with Resqcol Duo

An innovative dual-release product for managing and controlling all types of IBD symptoms

IBD: An Overview of Its Prevalence, Pathophysiology, and Management Strategies

Inflammatory bowel disease (IBD) results from the interaction between genetic and environmental factors which influence the immune responses. Inflammatory bowel diseases are mainly divided into ulcerative colitis (UC) and Crohn’s disease (CD). Crohn’s disease is similar to UC, both of which have been classified as chronic IBD and which cause digestive disorders and inflammation in the gastrointestinal tract. Some of the symptoms of CD and UC include diarrhea, abdominal pain, rectal bleeding, and weight loss. They are mainly characterized by inflammation. Both the diseases may occur in adolescents and adults and affect men and women equally.


In 2023, the global prevalence of inflammatory bowel disease (IBD) was estimated to exceed 7 million cases, and both incidence and prevalence continue to rise worldwide. The increasing burden is attributed to complex interactions between genetic susceptibility, environmental influences, and lifestyle changes that affect the gut microbiome. IBD typically presents as a chronic, relapsing condition that significantly impacts patients’ quality of life and poses growing challenges for healthcare systems worldwide

Resqcol Duo: Innovation in Digestive Health

Resqcol Duo offers a unique and effective solution, providing strong support for gut health and IBD symptom management.

  • Innovative double-release technology .(first portion of intestine -last portion of intestine.) Guaranteed protection and bioavailability of the synbiotic (prebiotic and probiotic), thanks to the cap-in-cap (CIC) system.
  • The first CIC product on the market to manage/control IBD symptoms.
  • A complete formula that offers a synergistic effect.
  • Rebalance the gut microbiota thanks to the synbiotic.
  • Scientifically supported. High-quality, clinically tested ingredients.

Innovative Double-Release Technology

Resqcol Duo’s unique dual-capsule system ensures precise delivery, directly targeting the specific site of the disease for optimal effectiveness.

  • EXTERNAL CAPSULE
    Intestinal absorption of the components: Boswellia serrata is absorbed in the intestine primarily through passive diffusion, but its poor water solubility limits bioavailability.
    Co-administration with black pepper can enhance absorption, as it increases solubility and improves absorption.

    COMPOSITION

    • Black pepper
    • Boswellia serrata
    • Vitamin D
    • Vitamin B12
  • INTERNAL CAPSULE
    Internal capsule that releases its ingredients after the external capsule has dissolved, targeting the last portion of the intestine.

    Probiotic protected from interactions with components of the inner capsule to guarantee stability of the synbiotic.
    The synbiotic corrects the gut microbiota imbalance (dysbiosis). Directly delivered at the intestine to colonize the gut.

    COMPOSITION

    Synbiotic:

    • Bifidobacterium longum
    • Saccharomyces boulardii
    • FOS
  • The design is based on innovative double-release technology, ensuring both capsules open in the intestine to precisely target the site of the disease.

Improve your intestinal health with clinically proven studies

Objetive

A randomized, double-blind, placebo-controlled trial was conducted to investigate the efficacy of B. longum supplementation for inducing remission in patients with active UC.

Results:

  • Rectal bleeding score significantly decreased in the B. longum group.
  • No significant decrease in the placebo group.
  • Patients receiving B. longum had a significant reduction in mucosal findings compared to the placebo group.

Objetive

A study was evaluated the effect of Saccharomyces boulardii on disease activity and nutritional markers in patients with Crohn’s disease (CD) who were in clinical remission. Researchers assessed whether long-term supplementation with S. boulardii could help maintain remission and improve overall health status.

Results:

  • Disease activity scores significantly decreased in patients taking S. boulardii.
  • Body weight and hemoglobin levels improved after supplementation.
  • Cholesterol levels increased within a healthy range.
  • Inflammatory and nutritional markers remained stable.
  • Only one patient experienced a flare-up, which was not related to S. boulardii.

Everything You Need to Know

Resqcol Duo is an innovative dual-release product designed for managing and controlling all types of IBD symptoms.

Resqcol Duo is a food supplement developed with an exclusive formula based on bioactive compounds from natural sources, probiotics, and vitamins. Its components work synergistically to help reduce inflammation in the intestinal tract, improve gut barrier function, and modulate intestinal permeability.

Resqcol Duo is indicated for patients with IBD:

Stand-alone treatment for patients in the remission phase: : 1 cap/day
Coadjuvant treatment alongside standard therapy: : 1 cap/day

  • A probiotic is a live microorganism that, when administered in adequate amounts, provides health benefits to the host.

  • A prebiotic is an ingredient that is selectively utilized by host microorganisms and confers beneficial health effects. Prebiotics serve as food for the beneficial microorganisms that inhabit our bodies.

  • According to the available technical information, the ingredients in Resqcol Duo are well tolerated and do not have side effects at the recommended doses. If you are pregnant or breastfeeding, consult your doctor before using this product.

About Aora Health

Nutraceutical Research and Development Company

We are part of AORA Health, a nutraceutical research and development company.

We create innovative, scientifically proven solutions with specific benefits designed to complement or replace pharmaceuticals.

Our mission is to improve people’s well-being through nutraceutical products with proven benefits and the backing of science.